Arch Biopartners Appoints Patrick Vink to Board of Directors
TORONTO, CANADA--(Marketwired - Dec. 12, 2016) - Arch Biopartners, Inc., (TSX VENTURE:ACH) (OTCBB:FOIFF) (Arch or the Company) is pleased to announce that Dr. Patrick Vink has joined its Board of Directors effective December 12th, 2016.
Dr. Vink is a well-known and active member of the European and North American life sciences community. In 2012, Dr. Vink joined Cubist Pharmaceuticals, a company focused on developing new antibiotics to treat drug-resistant bacterial infections. At Cubist, he served as Executive Vice President and Chief Operating Officer until the company was bought by Merck for a total transaction value of $9.5 billion in 2015.
Previously, he has held several leadership positions across the pharmaceutical industry, including Senior Vice President, Global head of Hospital Business and Biologics of Mylan Inc. (2008-2012), Head of Global Business Franchise Biopharmaceuticals at Novartis Sandoz (2002-2006), Vice President of International Business at Biogen (2000-2002) and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi (1997-2000).
Dr. Vink also was a member of the executive committee of the European Federation of Pharmaceutical Industries and Associations between 2013 and 2015. He is currently active as an advisor to the Life Sciences sector and serves on the board of directors of several companies including Acacia Pharma, Concordia International Corp, Piqur AG and Spero Therapeutics.
Claude Allary, Arch Board Member and former Co-Founder and Managing Director of Bionest Partners commented, "Patrick brings a strong industry background, an international network and tremendous experience with anti-bacterial drugs that will complement our current team, as we move our anti-bacterial candidate (AB569) to first-in-human trials in 2017."
Adrian Haigh, Arch Board Member and a senior executive of PTC Therapeutics stated, "We look forward to having Patrick join the Board of Directors, and take an active role in our strategic thinking, and help advise and execute our clinical trials for both AB569 and Metablok."
About Arch Biopartners
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, 'Borg' peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com
The Company currently has 53,849,679 common shares outstanding.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.